Gemcitabine + Cisplatin Chemotherapy
Treatment for Bladder Cancer
Typical Dosage: Gemcitabine 1000-1250 mg/m² IV day 1, 8; Cisplatin 70 mg/m² IV day 1 or 2 every 3 weeks
Effectiveness
70%
Safety Score
25%
Clinical Trials
112
Participants
10K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
25
DangerousModerateSafe
Treatment Details
Dosage Range
Gemcitabine 1000-1250 mg/m² IV day 1, 8; Cisplatin 70 mg/m² IV day 1 or 2 every 3 weeks
Time to Effect
3-6 months
Treatment Duration
3-6 months (4-6 cycles)
Evidence Quality
HIGHNumber Needed to Treat (NNT)
7(Treat 7 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
3(Treat 3 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$25,000
Monitoring:$7,500
Side Effect Mgmt:$15,000
Total Annual:$47,500
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATEICER
$120,000/QALY
QALYs Gained
0.7
Outcome-Based Costs
Cost per Responder
$105,555.56
Cost per Remission
$395,833.33
Gemcitabine + Cisplatin Chemotherapy Outcomes
for Bladder Cancer
Efficacy Outcomes
Overall Effectiveness
+70%
Response Rate
+45%
Remission Rate
+12%
Common Side Effects
Myelosuppression (neutropenia, thrombocytopenia)
+70%
Nausea/Vomiting
+60%
Fatigue
+80%
Nephrotoxicity (kidney damage)
+15%
Peripheral neuropathy
+15%
Sources:
Active Clinical Trials
6 active trials recruiting for Gemcitabine + Cisplatin Chemotherapy in Bladder Cancer
Perioperative Therapy Preoperative Chemotherapy Versus Chemoradiotherapy in Locally Advanced Gall Bladder Cancers
NCT02867865ACTIVE NOT RECRUITINGPHASE2, PHASE3
124 participants
INTERVENTIONAL
Mumbai, India
Started: Sep 6, 2016
Neoadjuvent Dose-dense Gemcitabine and Cisplatin In Muscle Invasive Bladder Cancer
NCT07184021NOT YET RECRUITINGPHASE2
30 participants
INTERVENTIONAL
Asyut, Egypt
Started: Sep 1, 2025
Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer
NCT02170090ACTIVE NOT RECRUITINGPHASE3
789 participants
INTERVENTIONAL
Bankstown, Australia +66 more
Started: Apr 1, 2014
Neoadjuvant Upper Tract Invasive Cancer Trial (NAUTICAL)
NCT04574960RECRUITINGPHASE3
14 participants
INTERVENTIONAL
Ottawa, Canada +1 more
Started: Feb 8, 2021
Surveillance of the Genetic Signature in Circulating Tumor DNA for Guiding Adjuvant Chemotherapy in Urothelial Carcinoma
NCT06257017RECRUITINGPHASE2
20 participants
INTERVENTIONAL
Hong Kong, Hong Kong
Started: Feb 2, 2024
Partial Cystectomy & Extended Pelvic Lymph Node Dissection With SOC Perioperative Systemic Therapy
NCT06290687RECRUITINGPHASE2
40 participants
INTERVENTIONAL
Cleveland, United States
Started: Sep 1, 2026
Completed Clinical Trials
4 completed trials for Gemcitabine + Cisplatin Chemotherapy in Bladder Cancer
A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer
NCT03661320COMPLETEDPHASE3
855 participants
INTERVENTIONAL
Tucson, United States +171 more
Started: Nov 6, 2018
Neoadjuvant Chemotherapy in Locally Advanced Bladder Cancer
NCT01801644COMPLETEDNA
60 participants
INTERVENTIONAL
Vienna, Austria
Started: Apr 1, 2007
Celecoxib With Chemotherapy in Localized, Muscle-Invasive Bladder Cancer
NCT02885974COMPLETEDPHASE1
22 participants
INTERVENTIONAL
Houston, United States +1 more
Started: Dec 1, 2016
Gemcitabine, Cisplatin, and Sunitinib (GC-S) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer
NCT00847015COMPLETEDPHASE2
18 participants
INTERVENTIONAL
Basking Ridge, United States +4 more
Started: Feb 1, 2009
Showing 20 of 121 total trials